Form 4: Enanta Pharmaceuticals Chief Scientific Officer Sells Shares to Cover Taxes

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, sold 1,595 shares of common stock to cover withholding taxes related to the settlement of restricted stock units.

Summary

• Or Yat Sun, the Chief Scientific Officer of Enanta Pharmaceuticals, sold 1,595 shares of common stock on December 1, 2024.
• The sale was executed to cover withholding taxes due from the settlement of restricted stock unit awards.
• The shares were sold at a price of $8.6 per share.
• Following the transaction, Or Yat Sun directly owns 371,700 shares of Enanta Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Similar transactions are common across the pharmaceutical and biotech industries where stock-based compensation is a significant part of executive pay.
• Many executives at comparable companies such as Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD) regularly file Form 4s for similar transactions related to stock options and restricted stock units.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes.

Key Dates

Keywords

Enanta Pharmaceuticals, insider trading, stock sale, Form 4, Or Yat Sun, restricted stock units, withholding taxes, ENT, Chief Scientific Officer